What question did this study set out to answer?

To explore the effectiveness of ERK inhibition in treating MEK1-mutant histiocytoses.

December 18, 2025Cancer Discovery

RAF-independent MEK1 -mutant Histiocytoses Respond to ERK Inhibition

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Implication

Analysis reveals clinical data indicating improved progression-free outcomes in histiocytic neoplasms with MEK1 mutations, suggesting ERK inhibition as a viable treatment strategy.

Key Points

To explore the effectiveness of ERK inhibition in treating MEK1-mutant histiocytoses.
Utilized a large patient dataset including genomic and clinical data from 498 patients with histiocytoses.
Identified the MEK1E102_I103del mutation as a targetable alteration in histiocytoses.
Analyzed treatment responses to BRAF and MEK inhibitors.
MEK1/2 mutations were identified as the second most frequent alteration after BRAF mutations.
Patients with class 3 MEK mutations showed reduced progression-free outcomes.

Cite This Study

A 2025 study studied this question.

synapsesocial.com/papers/694344699670be6eea0c596f https://doi.org/10.1158/2159-8290.cd-rw2025-105

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals clinical data indicating improved progression-free outcomes in histiocytic neoplasms with MEK1 mutations, suggesting ERK inhibition as a viable treatment strategy.

RAF-independent MEK1 -mutant Histiocytoses Respond to ERK Inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

RAF-independent MEK1 -mutant Histiocytoses Respond to ERK Inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider